Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) filed an 8-K on January 23, 2014, reporting on its financial performance for the fiscal quarter ended December 31, 2013. The report highlights the company's earnings and provides updated guidance for fiscal year 2014. Key information for investors includes the reaffirmation of adjusted diluted earnings per share expectations, an increase in revenue growth forecasts, and specific guidance on adjusted operating income growth and margin expectations. The company also provided details on its expected free cash flow generation and capital expenditure plans for fiscal year 2014. Management emphasizes the use of non-GAAP financial measures to provide a more comprehensive view of operating performance, noting that reconciliations to GAAP are available. Investors should pay close attention to the forward-looking statements and guidance provided, as these will be critical for assessing future performance and valuation.
Key Highlights
- 1Announced fiscal quarter earnings for the period ending December 31, 2013.
- 2Reaffirmed expected adjusted diluted earnings per share from continuing operations for fiscal year 2014 in the range of $3.60 to $3.73.
- 3Increased revenue growth expectations for fiscal year 2014 to a range of 30 percent to 34 percent.
- 4Maintained expectation for adjusted operating income growth in the 12 percent to 16 percent range for fiscal year 2014.
- 5Expects an adjusted operating margin decline of 20 to 23 basis points in fiscal year 2014, attributed to new business onboarding and growth in high-volume brand pharmaceutical business.
- 6Continues to expect free cash flow generation between $500 million and $700 million for fiscal year 2014.
- 7Plans to spend approximately $500 million on share repurchases in fiscal year 2014, subject to market conditions.